Literature DB >> 34107346

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

J E Martin1, S Khalife-Hachem1, T Grinda2, M Kfoury3, S Garciaz4, F Pasquier5, J Vargaftig6, M Uzunov7, A Belhabri8, S Bertoli9, S Cotteret10, V Vergé10, A Renneville11, F Rosselli12, I Antony-Debre11, E Rouleau10, F Salviat13, O Caron14, S Delaloge14, P Pautier15, G Etienne16, C Recher9, N Vey4, S De Botton1, A Leary17, C Marzac10, J B Micol18.   

Abstract

Entities:  

Year:  2021        PMID： 34107346     DOI： 10.1016/j.annonc.2021.04.015

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.

Authors:  Anmol Baranwal; Christopher N Hahn; Mithun Vinod Shah; Devendra K Hiwase
Journal:  Curr Hematol Malig Rep       Date:  2022-08-20       Impact factor: 4.213

Review 2.  [Clonal hematopoiesis and solid neoplasms].

Authors:  Christopher Maximilian Arends; Frederik Damm
Journal:  Inn Med (Heidelb)       Date:  2022-09-23

3.  Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.

Authors:  Jennifer L Oliveira; Patricia T Greipp; Aruna Rangan; Aminah Jatoi; Phuong L Nguyen
Journal:  Blood Cancer J       Date:  2022-01-25       Impact factor: 11.037

Review 4.  PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Authors:  Clifford M Csizmar; Antoine N Saliba; Elizabeth M Swisher; Scott H Kaufmann
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.